# Ovid Therapeutics Inc. (OVID) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.80, market value $547 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Ovid Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 345.4×**. Each dollar of revenue is priced at 345.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.

## Profitability
- **Net margin: -240.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -13.3%**. Return on equity is negative because earnings are negative.
- **Return on assets: -22.9%**. Each dollar of assets produces -22.9% of profit.

## Growth
- **Revenue growth (1 yr): 1181.3%** (3-yr 69.0%/yr, 5-yr -10.5%/yr). Revenue grew 1181.3% over the last year, against -10.5% a year compounded over five years: growth is accelerating.

## Financial health
- **Current ratio: 8.97** (quick 8.97). Current assets cover the next year's liabilities 8.97 times.
- **Altman Z-score: 17.04**. A Z-score of 17.04 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Ovid Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Ovid Therapeutics Inc.; the consensus is strong_buy, with an average price target of $5.80 (+107% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 117.1%** (YTD 71.8%, 3-mo 16.7%). The shares are up 117.1% over twelve months including dividends.
- **From 52-week high: -9.8%** (150.0% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 1.33** (volatility 87%). Beta of 1.33 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=OVID · Page: https://foliofundamentals.com/stocks/ovid

Not investment advice.